Seven Fleet Capital Management Reports 0.5% Stake in CytomX Therapeutics, Inc.

On May 15, 2026, Seven Fleet Capital Management LP, along with its affiliates and Dr. Brian Liu, filed a Schedule 13G/A regarding their holdings in CytomX Therapeutics, Inc. (CTMX). The filing discloses that the reporting persons collectively beneficially own 1,085,398 shares of common stock, representing approximately 0.5% of the company's outstanding shares. This position is primarily held of record by Seven Fleet Master Fund LP, with Seven Fleet Capital Management serving as the investment manager. The filing notes a potential group membership with Longitude Capital Management Co. LLC due to certain internal policies, which could aggregate their deemed ownership to 7.0%. However, the reporting persons expressly disclaim group membership and beneficial ownership over any shares held by Longitude. This amendment reflects an increase from a previous 0.0% ownership position as of the last reported snapshot, though the current 0.5% stake remains below the typical 5% threshold for active reporting, indicating this filing may be part of ongoing regulatory compliance or group disclaimer efforts.